晚期非小细胞肺癌免疫治疗进展

The current and future road of immunotherapy for advanced non-small cell lung cancer

免疫治疗作为目前最具影响力的肿瘤治疗手段,已全面改变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗格局。综述了晚期NSCLC免疫治疗存在的诸多尚待解决的问题,如免疫联合治疗模式的组合和优化、免疫治疗耐药的机制和应对策略、寻找合适的免疫治疗相关生物标志物、特殊人群特征的免疫治疗以及免疫治疗相关毒性管理等。探讨了晚期NSCLC免疫治疗的现状和未来之路。

Immunotherapy,as the most influential tumor treatment method at present,has comprehensively changed the treatment pattern of advanced non-small cell lung cancer(NSCLC).However,there are still many unresolved issues in the immunotherapy of advanced NSCLC,such as the combination and optimization of immunotherapy combination models,the mechanism and response strategies of resistance in tumor immunotherapy,finding effective biomarkers for immunotherapy,exploring immunotherapy strategies with special population characteristics,and managing the toxic side effects of immunotherapy.This article proposes some issues and perspectives on the current status and future path of immunotherapy for advanced NSCLC,hoping to provide new ideas that are in line with the current immunotherapy for advanced NSCLC,and to provide readers with directions for thinking and future exploration.